medigraphic.com

2010, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2010; 48 (6)

Acinetobacter baumannii bacteremia

Aguirre-Avalos G, Mijangos-Méndez JC, Amaya-Tapia G

Language: Spanish
References: 76
Page: 625-634
PDF size: 56.61 Kb.


ABSTRACT

Acinetobacter baumannii has emerged as an important nosocomial pathogen. It is difficult to control and treat. The most seriously ill patients and those previously infected are more likely than others to be infected or colonized by A. baumannii. The epidemiology of A. baumannii infection is complex, with the coexistence of epidemic and endemic infections. The A. baumannii are the species isolated in 90 % of the nosocomial infections and in 92 % of the nosocomial bacteremias. The intensive care units presented the greater number of nosocomial bacteremias by A. baumannii. The most common sources of A. baumannii are respiratory tract, surgical wound, catheter, urinary tract and others. The most frequently clinical manifestation is sepsis and a fulminating course is observed when the patient presents septic shock. Progressive resistance of A. baumannii to antimicrobial limits the therapeutic options. The patients with A. baumannii multidrug-resistant present an excessive rate of attributed mortality, length of stay and costs.


REFERENCES

  1. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial Infections caused by gram-negative bacilli. Clin Infect Dis 2005;41(6):848-854.

  2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial blood-stream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-317.

  3. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. EPIC International Advisory Committee. JAMA 1995; 274(8):639-644.

  4. Ponce de León-Rosales SP, Molinar-Ramos F, Domínguez-Cherit G, Rangel-Frausto MS, Vázquez-Ramos VG. Prevalence of infections in intensive care units in Mexico: a multicenter study. Crit Care Med 2000;28(5):1316-1321.

  5. Vallés J, León C, Álvarez-Lerma F. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Spanish Collaborative Group for Infections in Intensive Care Units of Sociedad Española de Medicina Intensiva y Unidades Coronarias (SEMIUC). Clin Infect Dis 1997;24(3):387-395.

  6. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999;27(8):1421- 1428.

  7. ŠulgajiC V, CobeljiC M, JankoviC S, MiroviC V, MarkoviC- DeniC L, RomiC P, et al. Nosocomial bloodstream infections in ICU and non-ICU patients. Am J Infect Control 2005;33(6):333-340.

  8. Hugonnet S, Harbarth S, Ferrière K, Ricou B, Suter P, Pittet D. Bacteremic sepsis in intensive care: temporal trends in incidence, organ dysfunction, and prognosis. Crit Care Med 2003;31(2):390-394.

  9. McDonald LC, Banerjee SN, Jarvis WR. Seasonal variation of Acinetobacter infections: 1987-1996. Nosocomial Infections Surveillance System. Clin Infect Dis 1999;29(5):1133-1137.

  10. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000; 31(1):101-106.

  11. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. Medicine 1995;74(6):340-349.

  12. Siau H, Yuen KY, Ho PL, Wong SS, Woo PC. Acinetobacter bacteremia in Hong Kong: prospective study and review. Clin Infect Dis 1999;28(1):26-30.

  13. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospital: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000;31(3):690-697.

  14. Choi SH, Chou EJ, Kwak YG, Kim MY, Jun JB, Kim MN, et al. Clinical characteristics and outcomes of bacteremia caused by Acinetobacter species other than A. baumannii: comparison with A. baumannii bacteremia. J Infect Chemother 2006; 12(6):380-386.

  15. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24(4):284-295.

  16. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42(5):692-699.

  17. Theaker C, Azadian B, Soni N. The impact of Acinetobacter baumannii in the intensive care unit. Anaesthesia 2003;58(3):271-274.

  18. García-Garmendia JL, Ortiz-Leyba C, Garnacho- Montero J, Jiménez-Jiménez FJ, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med 1999; 27(9):1794-1799.

  19. Allen DM, Hartmann BJ. Acinetobacter species. En: Mandell GL, Bennet J, Dolin R, editores. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. Fifth edition. Philadelphia: Churchill Livingstone; 2000. p. 2339- 2344.

  20. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clin Microbiol Rev 1996;9(2):148-165. Disponible en http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC172888/ pdf/090148.pdf

  21. Rahal JJ, Urban C. Acinetobacter. Semin Respir Crit Care Med 2000;21(4):341-348.

  22. Euzéby JP. List of prokaryotic names with standing in nomenclature-genus Acinetobacter. Disponible en http://www.bacterio.cict.fr/a/acinetobacter.html

  23. Zeana C, Larson E, Sahni J, Bayuga SJ, Wu F, Della- Latta P. The epidemiology of multidrug-resistant Acinetobacter baumannii: Does the community represent a reservoir? Infect Control Hosp Epidemiol 2003;24(4):275-279.

  24. Rodríguez-BJ, Cisneros JM, Fernández CF, Rivera A, Vila J, Pascual, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 2004;25(10):819-824.

  25. Lortholary O, Fagon JY, HoI AB, Slama MA, Pierre J, Giral P, et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 1995;20(4): 790-796.

  26. Martínez PA, Ruiz GJ, Jaime SF, Simarro CE, Fernández LJ. Incidencia de colonización e infección por Acinetobacter baumannii en una UCI con situación de endemia. Análisis de factores de riesgo mediante un estudio de vigilancia. Enferm Infec Microbiol Clin 2002;20(5)194-199.

  27. Playford EG, Craig JC, Iredell JR. Carbapenemresistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and their consequences. J Hosp Infect 2007;65(3) 204-211.

  28. Wilks M, Wilson A, Warwick S, Price E, Kennedy D, Ely A, et al. Control of an outbreak of multidrugresistant Acinetobacter baumannii-calcoaceticus colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation. Infect Control Hosp Epidemiol 2006;27 (7):654-658.

  29. Wisplinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999;28(1):59-66.

  30. Basustaoglu AC, Kisa O, Sacilik SC, Ozyurt M, Yildiran ST. Epidemiological characterization of hospital-acquired Acinetobacter baumannii isolates from a 1500-bed teaching hospital by phenotypic and genotypic methods. J Hosp Infect 2001;47(3): 246-249.

  31. Huang YC, Su LH, Wu TL, Leu HS, Hsieh WS, Chang TM, et al. Outbreak of Acinetobacter baumannii bacteremia in a neonatal intensive care unit: Clinical implications and genotyping analysis. Pediatr Infect Dis J 2002;21(2):1105-1109.

  32. Pei-Chun C, Li-Min H, Hui-Chi L, Luan-Yin C, Mei- Ling C, Chun-Yi L, et al. Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2007;28 (4):423-429.

  33. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002; 8(8):827-832.

  34. Go ES, Urban C, Burns J, Kreigswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polimyxin B and sulbactam. Lancet 1994;344 (8933):1329-1332.

  35. El Shafie SS, Alishaq M, Leni-García M. Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in trauma intensive care unit. J Hosp Infect 2004;56(2):101-105.

  36. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36(10):1268-1274.

  37. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-Buisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 1994;32(11): 2677-2681.

  38. Das I, Lambert P, Hill D, Noy M, Bion J, Elliot T. Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units. J Hosp Infect 2002;50(2)110-114.

  39. Villers D, Espaze E, Coste BM, Giauffret F, Ninin E, Nicolas F, et al. Nosocomial Acinetobacter baumannii infections. Microbiological and clinical epidemiology. Ann Intern Med 1998;129(3): 182-189.

  40. Abbo A, Navon-Venezia S, Hammeer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrugresistant Acinetobacter baumannii. Emerg Infect Dis 2005;11(1):22-29.

  41. García GJ, Ortiz LC, Garnacho MJ, Jiménez JF, Pérez PC, Barrero AA, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001;33(7):939-946.

  42. Martró E, Hernández A, Ariza J, Domínguez MA, Matas L, Argerich MJ, et al. Assessment of Acinetobacter baumannii susceptibility to antiseptics and disinfectants. J Hosp Infect 2003;55(1):39-46.

  43. Fillaux J, Dubouix A, Conil JM, Laguerre J, Marty N. Retrospective analysis of multidrug-resistant Acinetobacter baumannii strains isolated during a 4-year period in a university hospital. Infect Control Hosp Epidemiol 2006;27(7):647-653.

  44. Rodríguez-BJ, Pascual A, Gálvez J, Muniain MA, Ríos MJ, Martínez ML, et al. Bacteremias por Acinetobacter baumannii: características clínicas y pronósticas. Enferm Infec Microbiol Clin 2003;21(5): 242-247.

  45. Ayan M, Durmaz R, Aktas E, Durmaz B. Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter baumannii infec tion in a teaching hospital. J Hosp Infect 2003;54 (1):39-45.

  46. Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, García GJ, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22(6):1026-1032.

  47. Nan-Yao L, Hsin-Chun L, Nai-Ying K, Chia-Ming C, Hsin-I S, Chi-Jung W, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007;28(6):713-719.

  48. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007;13(2): 196-198.

  49. Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2005;38(2):127-136.

  50. Grupper M, Sprecher H, Mashiach T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007;28(3):293-298.

  51. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003;29(3):471-475.

  52. Vallés J, Rello J, Ochagavía A, Garnacho J, Alcalá MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003;123(5):1615-1624.

  53. Wang JT, McDonald LC, Chang SC, Ho M. Community- acquired Acinetobacter baumannii bacteremia in adult patients in Taiwan. J Clin Microbiol 2002; 40(4):1526-1529.

  54. Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006;129(1):102-109.

  55. Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2005;53(4):274-278.

  56. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34(11):1425-1430.

  57. Garnacho-MJ, Ortiz LC, Jiménez JF, Barrero AA, García GJ, Bernabeu WM, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colestin: a comparison with imipenemsusceptible VAP. Clin Infect Dis 2003;36(9):1111- 1118.

  58. Garnacho J, Sole-Violan J, Sa-Borges M, Díaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003;31 (10):2478-2482.

  59. Garnacho MJ, Ortiz LC, Fernández HE, Aldabó PT, Cayuela A, Márquez VJ, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005;31(5):649-655.

  60. Davis KA, Morán KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005;11(8): 1218-1224.

  61. Jiménez-Mejías ME, Pachón J, Becerril B, Palomino- Nicás J, Rodríguez-Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997;24:932-935.

  62. Siegman-Igra Y, Bar-Yosef S, Gorea A, Avram J. Nosocomial Acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review. Clin Infect Dis 1993;17(5):843-849.

  63. Cisneros JM, Rodríguez-Baño J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002;8(11):687-693.

  64. Oteo J, García-Estébanez C, Migueláñez S, Campos J, Martí S, Vila J, et al. Genotypic diversity of imipenem resistant isolates of Acinetobacter baumannii in Spain. J Infect 2007; 55(3):260-266.

  65. Peleg AY, Franklin C, Bell JM, Spelman DW. Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia. Infect Control Hosp Epidemiol 2006; 27(7):759-761.

  66. Stephens C, Francis SJ, Abell V, DiPersio JR, Wells P. Emergence of resistant Acinetobacter baumannii in critically ill patients within an acute care teaching hospital and a long-term acute care hospital. Am J infect Control 2007;35(4):212-215.

  67. Aguirre-Ávalos G, Quintero-Rojas MV, Corona- García V, Zavala-Silva ML, Coronado-Magaña H, Rodríguez-Hinojosa J, et al. Multidrug-resistant Acinetobacter baumannii infections from critically ill patients. En: The 41st Annual Meeting of IDSA; 2003 Oct 9-12; San Diego, CA. 2003.

  68. Pandey A, Kapil A, Sood S, Goel V, Das B, Seth P. In vitro activities of ampicillin-sulbactam and amoxicillin-clavulanic acid against Acinetobacter baumannii. J Clin Microbiol 1998;36(11):3415-3416.

  69. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, et al. Colistin as salvage therapy for nosocomial infections caused by multidrugresistant bacteria in the ICU. Int J Antimicrob Agents 2006;28(4):366-369.

  70. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007;13(1):97-103.

  71. Choi JY, Park YS, Kim CO, Yoon HJ, Shin SY, Kim YA, et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J 2005;35 (10):599-603.

  72. Markogiannakis A, Fildisis G, Tsiplakou S, Ikonomidis A, Koutsoukou A, Pournaras S, et al. Croos-transmission of multidrug-resistant Acinetobacter baumannii clonal strains causing episodes of sepsis in a Trauma Intensive Care Unit. Infect Control Hosp Epidemiol 2008;29(5):410-417.

  73. Fierobe L, Lucet JC, Decré D, Muller-Serieys C, Deleuze A, Joly-Guillou ML, et al. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol 2001;22(1):35-40.

  74. Aguirre-Ávalos G, Mijangos-Méndez JC, Zavala- Silva ML, Coronado-Magaña H, Amaya-Tapia G. Bacteremia por Acinetobacter baumannii en pacientes en estado crítico. Gac Med Mex 2009;145 (1):21-25.

  75. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falangas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008;62 (1):45-55.

  76. Principe L, D Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrobiol 2009;8:1-18.




2020     |     www.medigraphic.com